vcam1

Elsibucol (AGI 1096) is a VCAM1 inhibitor for the study of organ transplant rejection.Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. It lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury.

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and no intrinsic sympathomimetic activity.

Anti-VCAM1/CD106 Antibody is a monoclonal antibody targeting vascular cell adhesion molecule-1 (VCAM1/CD106). It inhibits leukocyte recruitment to inflammatory sites and tumor tissues by blocking the interaction between VCAM1 and integrin VLA-4.

VCAM1 binding peptide is a molecule that binds to VCAM1, with the sequence VHPKQHRGGSKGC.

2,4-Diamino-6-hydroxypyrimidine (DAHP) (DAHP) is a selective, specific inhibitor of GTP cyclohydrolase I, the rate limiting step for de novo pterin synthesis

Iron sucrose (Sucroferric oxyhydroxide) is treatment of iron deficiency anemia.

Ethyl linoleate is a natural product.

Phellopterin is a partial agonist of the central benzodiazepine receptors in vitro. Phellopterin shows a cytotoxic effect on RAW264.7 cell at the concentration from 40 to 400 μM. Phellopterin reduce TNF-alpha-induced VCAM-1 expression through regulation o

Natalizumab is a recombinant humanized monoclonal antibody and a humanized monoclonal antibody inhibitor that selectively targets α4 integrin (CD49d). Natalizumab binds to the α4β1 heterodimer and blocks its interaction with vascular cell adhesion molecule 1. Natalizumab also prevents lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses, and is used in the study of relapsing-remitting multiple sclerosis and Crohn’s disease. Natalizumab possesses anti-inflammatory and immunomodulatory activity, inhibiting the adhesion, retention, and transendothelial migration of immune cells, and reducing the infiltration of inflammatory cells into the central nervous system or affected sites. Natalizumab is also being studied for autoimmune or inflammation-related diseases such as B-cell lymphoma and non-infectious uveitis.

Etrolizumab (rhuMAb Beta7) is a humanized intestinal-selective anti-β7 integrin monoclonal antibody that selectively blocks the transport and retention of lymphocytes in the intestinal tract for the study of inflammatory bowel disease (IBD).

Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is an IgG1, κ inhibitor antibody derived from rats, specifically targeting mouse CD106/VCAM-1.

CAM741 is a novel selective inhibitor of vascular cell adhesion molecule 1 (VCAM1) synthesis in endothelial cells, blocking the process of cotranslational translocation, which is dependent on the signal peptide of VCAM1.

2'-Hydroxychalcone is a drug synthesis intermediate for the synthesis of flavonoids. 2'-Hydroxychalcone loaded in nanoemulsion showed fungicidal activity against Coccidioides parapsilosis in Danio rerio model.2'-Hydroxychalcone induced cytotoxicity through oxidative stress in lipid-loaded Hepg2 cells.2'-Hydroxychalcone inhibited the induction of ICAM-1, VCAM-α, tumor necrosis factor-α, and tumor necrosis factor-alpha as determined by reverse transcription-polymerase chain reaction determined by tumor necrosis factor-alpha induces steady-state transcript levels of ICAM-1, VCAM-1, and E-selectin, and therefore may interfere with the transcription of their genes.